The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: Contemporary estimates of average years of life lost

April K.S. Salama; Nicole De Rosa; Randall P. Scheri; James E. Herndon; Douglas S. Tyler; Jennifer Marcello; Scott K. Pruitt; Amy P. Abernethy

doi:10.3109/07357907.2012.726387

The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: Contemporary estimates of average years of life lost

April K.S. Salama, Nicole De Rosa, Randall P. Scheri, James E. Herndon, Douglas S. Tyler, Jennifer Marcello, Scott K. Pruitt, Amy P. Abernethy

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.

Original language	English (US)
Pages (from-to)	637-641
Number of pages	5
Journal	Cancer Investigation
Volume	30
Issue number	9
DOIs	https://doi.org/10.3109/07357907.2012.726387
State	Published - Nov 1 2012
Externally published	Yes

Keywords

Life expectancy
Melanoma
Mortality
Potential years of life lost
Survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3109/07357907.2012.726387

Fingerprint Dive into the research topics of 'The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: Contemporary estimates of average years of life lost'. Together they form a unique fingerprint.

Cite this

Salama, A. K. S., Rosa, N. D., Scheri, R. P., Herndon, J. E., Tyler, D. S., Marcello, J., Pruitt, S. K., & Abernethy, A. P. (2012). The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: Contemporary estimates of average years of life lost. Cancer Investigation, 30(9), 637-641. https://doi.org/10.3109/07357907.2012.726387

The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma : Contemporary estimates of average years of life lost. / Salama, April K.S.; Rosa, Nicole De; Scheri, Randall P.; Herndon, James E.; Tyler, Douglas S.; Marcello, Jennifer; Pruitt, Scott K.; Abernethy, Amy P.

In: Cancer Investigation, Vol. 30, No. 9, 01.11.2012, p. 637-641.

Research output: Contribution to journal › Article › peer-review

Salama, April K.S. ; Rosa, Nicole De ; Scheri, Randall P. ; Herndon, James E. ; Tyler, Douglas S. ; Marcello, Jennifer ; Pruitt, Scott K. ; Abernethy, Amy P. / The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma : Contemporary estimates of average years of life lost. In: Cancer Investigation. 2012 ; Vol. 30, No. 9. pp. 637-641.

@article{90bd34012fad4e5fb5983c4c02ccffc9,

title = "The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: Contemporary estimates of average years of life lost",

abstract = "Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.",

keywords = "Life expectancy, Melanoma, Mortality, Potential years of life lost, Survival",

author = "Salama, {April K.S.} and Rosa, {Nicole De} and Scheri, {Randall P.} and Herndon, {James E.} and Tyler, {Douglas S.} and Jennifer Marcello and Pruitt, {Scott K.} and Abernethy, {Amy P.}",

year = "2012",

month = nov,

day = "1",

doi = "10.3109/07357907.2012.726387",

language = "English (US)",

volume = "30",

pages = "637--641",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma

T2 - Contemporary estimates of average years of life lost

AU - Salama, April K.S.

AU - Rosa, Nicole De

AU - Scheri, Randall P.

AU - Herndon, James E.

AU - Tyler, Douglas S.

AU - Marcello, Jennifer

AU - Pruitt, Scott K.

AU - Abernethy, Amy P.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.

AB - Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.

KW - Life expectancy

KW - Melanoma

KW - Mortality

KW - Potential years of life lost

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84867721516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867721516&partnerID=8YFLogxK

U2 - 10.3109/07357907.2012.726387

DO - 10.3109/07357907.2012.726387

M3 - Article

C2 - 23020583

AN - SCOPUS:84867721516

VL - 30

SP - 637

EP - 641

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 9

ER -